(Fighting New Crown Pneumonia) Academician of the Chinese Academy of Engineering: China's New Crown vaccine development progress is among the internationally advanced
China News Service, Beijing, March 17 (Reporter Li Yanan) Wang Junzhi, an academician of the Chinese Academy of Engineering, said in Beijing on the 17th that the development of China's new crown vaccine is currently in the international advanced stage and will not be slower than abroad.
On the same day, the State Council's joint prevention and control mechanism held a press conference on the latest development of drug vaccines and testing reagents.
Wang Junzhi said that China established a scientific research group at the outset of the epidemic, and immediately incorporated vaccine research and development into the five major research directions, giving targeted priority support, and deployed animal model research closely related to vaccine research and development in advance to capture inactivated vaccines. , Genetic engineering recombinant subunit vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine five technical directions, selected eight advantageous teams, identified nine tasks to promote.
"At present, the five major technological directions of vaccines are progressing smoothly. The first nine tasks identified have completed most of the preclinical research. Most of the research and development teams can complete the preclinical research in April and gradually start clinical trials. The team is moving faster. "Wang Junzhi said.
Wang Junzhi also particularly emphasized that units that have made rapid progress in research and development have submitted clinical trial application materials to the State Food and Drug Administration, and have already carried out clinical trial program demonstration, recruitment of volunteers and other related work, pending the approval of the State Drug Administration in accordance with relevant laws and regulations. After that, clinical trials started. "It should be said that the development of China's new crown vaccine is currently in the forefront of international advancement and will not be slower than abroad."
In terms of vaccine safety, Wang Junzhi said that stable production processes and quality control standards have been established in pharmaceutical research to ensure that qualified vaccine samples are prepared. After obtaining vaccine samples, infection animal models are used to evaluate vaccine immunogenicity. And protection effect, in the evaluation of vaccine safety, at least a single dose (acute) toxicity and repeated dose (long-term toxicity) of the animal should be evaluated for new infectious diseases.
Wang Junzhi said that every aspect of vaccine research and development has corresponding technical regulations that can be followed, and these regulations and technical requirements are consistent with international standards such as WHO. "In general, we must first produce a qualified vaccine sample and prove its safety and effectiveness in animal experiments before entering clinical trials." (End)